ABSTRACT

In the present research work animal model studies were performed to determine gastrointestinal (GI) absorption and elimination rate of pitavastatin. The in vitro evaluation of the prepared solid-snedds release of pitavastatin with the selected oils (labrafac lipophilewl1349, capmul MCM), surfactants (tween 80), co surfactants (egg lecithin) confirmed the usefulness compared to the remaining oils, Surfactants and co surfactants for the drug that are selected. From the in vivo evaluation studies of optimized formulation, the results are as follows: peak plasma concentration (Cmax) of the pure pitavastatin and RPTV1 (rabbit dose optimized pitavastatin) were 524 ± 6.49 ng/ml and 469.9 ± 12.09 ng/ml. Time required to extend maximal concentration (Tmax) in case of formulation (RPTV1) was increased from 1 to 2 h in comparison to pure drug Pitavastatin, AUC0-t was found to be 912.93 ± 1.80 ng.h/ml and 2982.5 ± 0.74 ng.h/ml for pure pitavastatin and formulation RPTV1. For pitavastatin and formulation (RPTV1) elimination rate constant was observed that 0.680 ± 0.001 h-1 and 0.560 ± 0.0007 h- 1. The t1/2 for pure pitavastatin was found to be 1.02 ± 0.007 h and 1.23 ± 0.01 h for RPTV1. Drug releases from the tablet (RPTV1) were increased in comparison with the pure drug in rabbit shows that drug plasma levels maintained up to 12 h. Thus it indicates that improved bioavailability of optimized s-snedds (solid self nano emulsifying drug delivery systems). Keywords: Pitavastatin, S-snedds, Cmax. AUC, Kel, Bioavailability
Publication date: 01/10/2023

https://ijbpas.com/pdf/2023/October/MS_IJBPAS_2023_7522.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.10.7522